Akcea to license investigative antisense therapy AKCEA-ANGPTL3-LRx to Pfizer

Under the terms of the worldwide exclusive licensing agreement, Pfizer will pay an upfront license fee of $250m to Akcea and Ionis. The fee will be split equally